Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.56 |
| ▸ | TACR2 | P21452 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581450 | 0.91 | TACR3 (0.56) | TACR3TACR2TSHRKDM4EMEN1 | |
| SCHEMBL1581275 | 0.87 | TACR3 (0.59) | TACR3TACR2OPRM1 | |
| SCHEMBL6450084 | 0.86 | TACR3 (0.72) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6448747 | 0.86 | TACR3 (0.72) | TACR3TACR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1581180 | 0.85 | TACR3 (0.58) | TACR3TACR2TSHRKDM4EMEN1 | |
| SCHEMBL1581668 | 0.85 | TACR3 (0.78) | TACR3TACR2TSHRMEN1ALDH1A1 | |
| SCHEMBL1581253 | 0.85 | TACR3 (0.78) | TACR3TACR2TSHRMEN1ALDH1A1 | |
| SCHEMBL1581228 | 0.85 | TACR3 (0.58) | TACR3TACR2TSHRKDM4EMEN1 | |
| SCHEMBL3329491 | 0.85 | TACR3 (0.58) | TACR3TACR2TSHRKDM4EMEN1 | |
| SCHEMBL2013058 | 0.85 | TACR3 (0.59) | TACR3TACR2TSHRKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-1928835-B1 | ALKYL SULFOXIDE QUINOLINES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1928835-B1 | ALKYL SULFOXIDE QUINOLINES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2007035158-A1 | ALKYL SULFOXIDE QUINOLINES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | MSR1, KCNQ3, KCNA3 | TACR3 13/4885TACR2 6/4885TSHR 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.